Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats

Cytokine

Volumn 53, Issue 2, 2011, Pages 223-230

  Subeq, Yi Maun ^a   Ke, Chen Yen ^a   Lin, Nien Tsung ^a   Lee, Chung Jen ^b   Chiu, Yi Han ^a   Hsu, Bang Gee ^a,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Chlorhexidine digluconate; Peritoneal fibrosis; Transforming growth factor 1; Valsartan

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHLORHEXIDINE GLUCONATE; COLLAGEN; FIBRONECTIN; GLUCOSE; TRANSFORMING GROWTH FACTOR BETA1; UREA; VALSARTAN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIALYSATE LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; HEART RATE; HISTOPATHOLOGY; LIVER; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOOD PRESSURE; CHLORHEXIDINE; GLUCOSE; HEART RATE; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; STAINING AND LABELING; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; VALINE;

RATTUS;

EID: 78651104122     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.11.004     Document Type: Article

References (25)

1. Yung S., Chan T.M. Preventing peritoneal fibrosis - insights from the laboratory. Perit Dial Int 2003, 23(Suppl. 2):S37-S41.
2. Witowski J., Jörres A. Preventing peritoneal fibrosis - an ace up our sleeve?. Perit Dial Int 2005, 25:25-29.
3. Nessim S.J., Perl J., Bargman J.M. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?. Kidney Int 2010, 78:23-28.
4. Noh H., Ha H., Yu M.R., Kim Y.O., Kim J.H., Lee H.B. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005, 25:38-47.
5. Black H.R., Bailey J., Zappe D., Samuel R. Valsartan: more than a decade of experience. Drugs 2009, 69:2393-2414.
6. Mancini G.B., Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med 2005, 28:118-126.
7. Xu W., Song S., Huang Y., Gong Z. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 2006, 21:1250-1256.
8. Wu K., Zhou T., Sun G., Wang W., Zhang Y., Zhang Y., et al. Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue. Cell Mol Immunol 2006, 3:213-220.
9. Yoshida K., Kobayashi N., Ohno T., Fukushima H., Matsuoka H. Cardioprotective effect of angiotensin II type 1 receptor antagonist associated with bradykinin-endothelial nitric oxide synthase and oxidative stress in Dahl salt-sensitive hypertensive rats. J Hypertens 2007, 25:1633-1642.
10. Wu W.T., Hu T.M., Lin N.T., Subeq Y.M., Lee R.P., Hsu B.G. Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats. Cytokine 2010, 49:155-162.
11. Ke C.Y., Lee C.C., Lee C.J., Subeq Y.M., Lee R.P., Hsu B.G. Aliskiren ameliorates chlorhexide digluconate-induced peritoneal fibrosis in rats. Eur J Clin Invest 2010, 40:301-309.
12. Wood J.M., Schnell C.R., Cumin F., Menard J., Webb R.L. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005, 23:417-426.
13. Ro Y., Hamada C., Inaba M., Io H., Kaneko K., Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007, 22:2838-2848.
14. Saito H., Kitamoto M., Kato K., Liu N., Kitamura H., Uemura K., et al. Tissue factor and factor v involvement in rat peritoneal fibrosis. Perit Dial Int 2009, 29:340-351.
15. Fusshoeller A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol 2008, 23:19-25.
16. Faull R.J. Bad and good growth factors in the peritoneal cavity. Nephrology 2005, 10:234-239.
17. Margetts P.J., Kolb M., Galt T., Hoff C.M., Shockley T.R., Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001, 12:2029-2039.
18. Duman S., Sen S., Duman C., Oreopoulos D.G. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005, 28:156-163.
19. Carvajal G., Rodríguez-Vita J., Rodrigues-Díez R., Sánchez-López E., Rupérez M., Cartier C., et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008, 74:585-595.
20. Aroeira L.S., Aguilera A., Sánchez-Tomero J.A., Bajo M.A., del Peso G., Jiménez-Heffernan J.A., et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007, 18:2004-2013.
21. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004, 15:1-12.
22. Sauter M., Cohen C.D., Wörnle M., Mussack T., Ladurner R., Sitter T. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007, 27:167-172.
23. Jing S., Kezhou Y., Hong Z., Qun W., Rong W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology 2010, 15:27-32.
24. Ersoy R., Celik A., Yilmaz O., Sarioglu S., Sis B., Akan P., et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007, 27:424-431.
25. Nakamoto H., Imai H., Fukushima R., Ishida Y., Yamanouchi Y., Suzuki H. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008, 28(Suppl 3):S83-S87.